About the study
About the study
A1chieve is a 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice run by Novo Nordisk.
A1chieve[1,2] is a 60,000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice run by Novo Nordisk. The study evaluated adverse events and effectiveness of premix (biphasic insulin aspart 30 [NovoMix 30]), basal (insulin detemir [Levemir]), and meal-time (insulin aspart [NovoRapid]) insulin analogs in people with type 2 diabetes in near-routine clinical practice. A1chieve is an international, prospective, multi-centre, open-label, non-interventional, 24-week study of people with type 2 diabetes using an insulin analog. The study recruited 60 000 people from 28 countries across four continents (Asia, Africa, South America, and Europe). The primary aim of the study is to assess the adverse event profile of the study insulins in routine clinical practice, including rates of hypoglycemia. In addition, effectiveness (HbA(1c), fasting plasma glucose, and postprandial plasma glucose) and patient quality of life outcomes were measured. Comprehensive epidemiological data were collected at baseline, including recent plasma glucose results and hypoglycemic episodes, prevalence of diabetes-related complications, and measures of current standards of care. Thus, A1chieve provides important information about how insulin analogs perform in daily clinical practice.
1. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. Diabetes Research and Clinical Practice 94 (2011) 353-363.
2. Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: Results from the A1chieve observational study. Diabetes Research and Clinical Practice 94 (2011) 364-370.